Avacta’s Pre|CISION® Technology Shows Superior Tumor Targeting in ADC Comparisons
Event summary
- Avacta presented new data comparing its pre|CISION® payload delivery system with approved ADCs Enhertu® and Datroway® at Science Day 2026.
- AVA6103 demonstrated faster tumor penetration and higher payload concentration than Enhertu® and Datroway®.
- AVA6207 dual-payload delivery showed durable responses in FAP-low/HER2-positive cancer models where Enhertu® failed.
- Avacta plans to publish findings in a peer-reviewed journal and at an upcoming academic meeting.
The big picture
Avacta’s data suggests its pre|CISION® platform could offer meaningful improvements in tumor targeting over current ADCs, potentially expanding treatment options for cancer patients. The comparison with Enhertu® and Datroway® highlights the strategic importance of payload delivery kinetics in oncology. If validated, this could position Avacta as a key player in the next generation of targeted cancer therapies.
What we're watching
- Technology Validation
- Whether peer-reviewed publication will validate pre|CISION®'s advantages over existing ADCs.
- Clinical Translation
- The pace at which dual-payload data from AVA6207 will advance into human trials.
- Competitive Positioning
- How Avacta differentiates its tumor-activated delivery against established ADC players.
Related topics